DR. ROGER J. POMERANTZ, MD
Osteopathic Medicine at Harvest Hill Dr, Chalfont, PA
License number
Pennsylvania MD042740L
Category
Osteopathic Medicine
Type
Infectious Disease
License number
Pennsylvania 52844
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
711 Harvest Hill Dr, Chalfont, PA 18914
Phone
(609) 933-7321
Personal information
See more information about ROGER J. POMERANTZ at radaris.comName
Address
Phone
711 Harvest Hill Dr, Chalfont, PA 18914
711 Harvest Hill Dr, Chalfont, PA 18914
Professional information
Dr. Roger J Pomerantz, Chalfont PA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
711 Harvest Hill Dr, Chalfont 18914
(215) 997-1461 (Phone)
(215) 997-1461 (Phone)
Certifications:
Infectious Disease, 1996, Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1982
Johns Hopkins University / School of Medicine
Graduated: 1982
Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target
US Patent:
7226741, Jun 5, 2007
Filed:
Oct 17, 2003
Appl. No.:
10/688100
Inventors:
Hui Zhang - Philadelphia PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911, 435 9133
Abstract:
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.
Method Of Treating Residual Hiv-I Disease
US Patent:
2002004, Apr 25, 2002
Filed:
May 21, 2001
Appl. No.:
09/861751
Inventors:
Roger Pomerantz - Chalfont PA, US
International Classification:
C12Q001/70, A61K045/00, A61K039/395
US Classification:
424/153100, 435/005000
Abstract:
The current therapeutic approach to treating patients with HIV-1 infection involves the use of one or more highly active antiretroviral therapeutics (HAART). While efficacious, this approach does not address the existance of latently infected cells. Such latently infected cells can be reactivated, resulting in the expression of infectious virus and reinitiation of the disease process. The present invention relates to a novel and highly efficacious approach to eradication of HIV-1. Patients that are treated with HAART are then treated with an intensification regimen wherein hydroxyurea and didanosine (ddI) are given to inhibit any residual viral replication. The therapeutic regimen is continued with the addition of compounds, such as OKT3 and IL-2, that activate latently infected cells, thereby stimulating the replication of any proviruses. These re-activated viruses are subsequently inhibited by the HAART and hydroxyurea/ddI therapeutics. Thus, the present invention provides a method of treating HIV-1 to eradicate any low-level viral replication and latently infected cells, thereby eliminating residual HIV-1 disease.
Cellular Targets For Treatment Of Retroviral Infection
US Patent:
2011008, Apr 14, 2011
Filed:
Jun 14, 2010
Appl. No.:
12/815125
Inventors:
Rene Daniel - Ambler PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
International Classification:
C12N 5/071
US Classification:
435366, 435325
Abstract:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
Method For Increasing Transduction Efficiency Of Recombinant Retroviral Vectors
US Patent:
5763242, Jun 9, 1998
Filed:
Feb 8, 1995
Appl. No.:
8/385446
Inventors:
Hui Zhang - Philadelphia PA
Roger J. Pomerantz - Chalfont PA
Roger J. Pomerantz - Chalfont PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12N 1500, C12N 1586, C12N 510
US Classification:
4351723
Abstract:
A method for improving the transduction efficiency of retroviral vectors into a host cell wherein the retroviral vectors are incubated with deoxyribonucleoside triphosphates prior to transduction into the host cell is provided.
Ribozyme-Mediated Gene Replacement
US Patent:
6077705, Jun 20, 2000
Filed:
May 14, 1997
Appl. No.:
8/856331
Inventors:
Lingxun Duan - North Wales PA
Mark A. Zern - Newtown PA
Roger J. Pomerantz - Chalfont PA
Mark A. Zern - Newtown PA
Roger J. Pomerantz - Chalfont PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C07H 2104, C12N 1585, C12Q 168
US Classification:
4353201
Abstract:
Methods of gene therapy, particular ribozyme-mediated gene replacement methods, are disclosed. Method of treating patients suffering from a disease associated with expression of an abnormal form of a gene, such as alpha-1 antitrypsin mutations, are disclosed. The methods comprise the steps of administering to such a patient a nucleic acid construct encoding a ribozyme and a nucleic acid construct comprising a ribozyme resistant gene encoding a wild type form of the gene product. Recombinant vectors and pharmaceutical compositions for practicing the methods are disclosed.
Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target
US Patent:
7498138, Mar 3, 2009
Filed:
Jun 4, 2007
Appl. No.:
11/809953
Inventors:
Hui Zhang - Philadelphia PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911
Abstract:
The HIV-1 protein Vif comprises a multimerization domain that allows Vif-Vif interaction and Vif multimerization, which is important for Vif function in the HIV-1 life-cycle. A method for screening for an antagonist of Vif comprises contacting the multimerization domain of Vif with a test compound that specifically binds the multimerization domain. Antagonists identified by the screening assay inhibit Vif multimerization. The antagonists inhibit essential functions of Vif and accordingly are useful as inhibitors of HIV-1 replication.
Cellular Targets For Treatment Of Retroviral Infection
US Patent:
7736848, Jun 15, 2010
Filed:
Mar 30, 2005
Appl. No.:
11/093692
Inventors:
Rene Daniel - Ambler PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
Assignee:
Fox Chase Cancer Center - Philadelphia PA
International Classification:
C12N 1/21, C12Q 1/701
US Classification:
435 5, 424 161, 435339
Abstract:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
In Situ Polymerase Chain Reaction
US Patent:
5750347, May 12, 1998
Filed:
Dec 12, 1996
Appl. No.:
8/764538
Inventors:
Omar Bagasra - Laurel Springs NJ
Roger J. Pomerantz - Chalfont PA
Roger J. Pomerantz - Chalfont PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 168, C12Q 170, C12P 1934, C07H 2104
US Classification:
435 6
Abstract:
The present invention concerns in situ polymerase chain reaction and provides methods and reagents for identifying cells containing at least one selected nucleic acid sequence which may be derived from the human immunodeficiency virus.
In Situ Polymerase Chain Reaction
US Patent:
5589333, Dec 31, 1996
Filed:
Apr 11, 1994
Appl. No.:
8/225491
Inventors:
Omar Bagasra - Laurel Springs NJ
Roger J. Pomerantz - Chalfont PA
Roger J. Pomerantz - Chalfont PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 168, C12Q 170, C12P 1934, C07H 2104
US Classification:
435 6
Abstract:
The present invention concerns in situ polymerase chain reaction and provides methods and reagents for identifying cells containing at least one selected nucleic acid sequence which may be derived from the human immunodeficiency virus.